294 related articles for article (PubMed ID: 21300092)
1. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
5. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
7. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
8. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
Lévy Y; Durier C; Lascaux AS; Meiffrédy V; Gahéry-Ségard H; Goujard C; Rouzioux C; Resch M; Guillet JG; Kazatchkine M; Delfraissy JF; Aboulker JP;
AIDS; 2006 Feb; 20(3):405-13. PubMed ID: 16439874
[TBL] [Abstract][Full Text] [Related]
9. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
[TBL] [Abstract][Full Text] [Related]
10. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
[TBL] [Abstract][Full Text] [Related]
11. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
[TBL] [Abstract][Full Text] [Related]
13. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
14. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy.
Hejdeman B; Boström AC; Matsuda R; Calarota S; Lenkei R; Fredriksson EL; Sandström E; Bratt G; Wahren B
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):860-70. PubMed ID: 15320990
[TBL] [Abstract][Full Text] [Related]
15. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
[TBL] [Abstract][Full Text] [Related]
18. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
19. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
20. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]